UK Public Sector Contracts & Tenders

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Oseltamivir and Zanamivir through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

The Supply of Diphtheria Antitoxin (2026) UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Diphtheria Antitoxin through this Request for Information (RFI), in accordance with the Procurement Act 2023. Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.

The UK Health Security Agency (UKHSA) is seeking to understand the market's ability to deliver digital technologies that support public health intervention activities such as, but not limited to, surveillance, infection identification, the management of cases, contacts and exposures during a health emergency. The objective of this Request for Information (RFI) is to inform future preparedness planning and ensure the UK has access to scalable, effective and deployable digital capabilities that can help reduce transmission, improve situational awareness and support public health interventions during a pandemic or other infectious disease emergency. The key dates for this RFI are as follows: RFI Published: 18th September 2026 RFI Response Deadline: 2nd October 2026 Specifically, UKHSA wishes to: I. Understand the current and emerging marketplace for digital technologies that could be deployed during a future pandemic or infectious disease incident to support the prevention, identification, monitoring and management of infection transmission among the population, across a range of pathogens and settings. II. Understand the intended purpose, use cases and operational objectives of technologies currently available or under development, including solutions not specifically designed for pandemic response but which may have utility in supporting infection control measures, population monitoring, exposure identification or public communications during a health emergency. III. Assess the effectiveness, maturity and performance characteristics of different intervention, surveillance and outbreak-management technologies, including evidence of impact, operational limitations and suitability for deployment across diverse settings such as communities, healthcare facilities, care homes, schools and other educational establishments, custodial environments, travel and transportation hubs, and workplaces. IV. Understand the costs associated with the implementation, operation and maintenance of technologies across different deployment scenarios, including infrastructure, licensing, support, integration and user adoption requirements, to inform assessments of affordability and value for money. V. Understand suppliers' manufacturing, delivery and operational capacity (inclusive of lead times), including their ability to rapidly scale deployment during a national emergency, and identify key dependencies, risks, constraints and mitigation approaches that may affect resilience of supply. VI. Assess industry capability to develop, adapt or configure bespoke digital solutions that support activities such as case management, contact tracing, exposure notification, outbreak investigation, provision of personalised advice, and wider population engagement, including the ability to provide interoperable data flows into UKHSA systems in near real time while meeting relevant legal, data protection, security and governance requirements. VII. Refine UKHSA's understanding of requirements by identifying innovative approaches, emerging technologies and alternative delivery models that may improve public health outcomes, operational effectiveness, user experience and scalability for Pandemic and other large scale public health incidents. VIII. Inform UKHSA's future commercial strategy and route-to-market approach, ensuring procurement requirements are proportionate, deliver value for money, maximise competition and innovation, and support the acquisition of capabilities that are fit for purpose during health emergencies. Should you wish to respond to this Request for Information or require more information, please follow the link below: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001wm4S4IAI&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

The key dates for this RFI are as follows: RFI Published: 28 August 2026 RFI Response: 11 September 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: The UKHSA Sequencing Laboratories in Bristol, Colindale, Manchester, and Porton Down offer nucleic acid sequencing services to support a variety of public health and clinical functions. These services currently include ongoing pathogen surveillance programmes, clinical metagenomics sequencing, and outbreak detection. As part of the UKHSA Pathogen Genomics Strategy and Pandemic Preparedness Programme, we are looking to maintain and expand the capacity and efficiency of our Genomics services. We therefore wish to explore available liquid handling robotics to support sequencing laboratory processing. Should you wish to respond to this Request for Information or require more information, please follow the link below: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001uBE2zIAG&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Doxycycline 10 pack through this Request for Information (RFI), in accordance with the Procurement Act 2023.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Pralidoxime Chloride through this Request for Information (RFI), in accordance with the Procurement Act 2023. Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.